 Increased expression of ICAM-1 has been observed within the inflamed intestinal mucosa of ulcerative colitis sufferers, where ICAM-1 over production correlated with disease activity.This suggests that ICAM-1 is a potential therapeutic target in the treatment of ulcerative colitis.Gram positive bacteria present in the lumen could be associated with extending the time of relapse for ulcerative colitis.